Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2529-2540

  Eich, Marcus ^a   Roos, Wynand Paul ^a   Nikolova, Teodora ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 O METHYLGUANINE; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; HISTONE H2AX; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DRUG INHIBITION; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; GUANINE; HUMANS; MELANOMA; METHYLNITRONITROSOGUANIDINE; PHOSPHORYLATION; PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84887428372     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53.
2. Shiloh Y. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu Rev Genet 1997;31: 635-62.
3. O'Driscoll M, Gennery AR, Seidel J, Concannon P, Jeggo PA. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair (Amst) 2004;3:1227-35.
4. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
5. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 2000;97:10389-94.
6. Jones RM, Petermann E. Replication fork dynamics and the DNA damage response. Biochem J 2012;443:13-26.
7. Nojima H. Protein kinases that regulate chromosome stability and their downstream targets. Genome Dyn 2006;1:131-48.
8. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39.
9. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, Hobson K, et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 2003;278:14806-11.
10. Stiff T, Walker SA, Cerosaletti K, Goodarzi AA, Petermann E, Concannon P, et al. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J 2006;25:5775-82.
11. Wang XQ, Redpath JL, Fan ST, Stanbridge EJ. ATR dependent activation of Chk2. J Cell Physiol 2006;208:613-9.
12. Beranek DT. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 1990;231: 11-30.
13. Kaina B, Fritz G, Mitra S, Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 1991;12: 1857-67.
14. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
15. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci U S A 1999;96:10764-9.
16. Roos W, Baumgartner M, Kaina B. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 2004;23:359-67.
17. Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine- DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta 2011;1816:179-90.
18. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 2004;66: 478-91.
19. Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 2010; 9:168-78.
20. Stojic L, Mojas N, Cejka P, Di Pietro M, Ferrari S, Marra G, et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 2004;18:1331-44.
21. Adamson AW, Beardsley DI, Kim WJ, Gao Y, Baskaran R, Brown KD. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell 2005;16:1513-26.
22. Debiak M, Nikolova T, Kaina B. Loss of ATM sensitizes against O6- methylguanine triggered apoptosis, SCEs and chromosomal aberrations. DNA Repair (Amst) 2004;3:359-68.
23. Nadkarni A, Shrivastav M, Mladek AC, Schwingler PM, Grogan PT, Chen J, et al. ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells. J Neurooncol 2012;110:349-57.
24. Shiloh Y, Becker Y. Kinetics of O6-methylguanine repair in human normal and ataxia telangiectasia cell lines and correlation of repair capacity with cellular sensitivity to methylating agents. Cancer Res 1981;41:5114-20.
25. Teo IA, Arlett CF. The response of a variety of human fibroblast cell strains to the lethal effects of alkylating agents. Carcinogenesis 1982; 3:33-7.
26. Samson L, Schwartz JL. Evidence for an adaptive DNA repair pathway in CHO and human skin fibroblast cell lines. Nature 1980;287:861-3.
27. Roos WP, Binder A, Bohm L. Determination of the initial DNA damage and residual DNA damage remaining after 12 hours of repair in eleven cell lines at low doses of irradiation. Int J Radiat Biol 2000;76:1493-500.
28. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007;67:2632-42.
29. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP- 31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003;22:8233-45.
30. Quiros S, Roos WP, Kaina B. Rad51 and BRCA2-New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS ONE 2011;6:e27183.
31. Parsons JL, Dianova II, Dianov GL. APE1-dependent repair of DNA single-strand breaks containing 30-end 8-oxoguanine. Nucleic Acids Res 2005;33:2204-9.
32. Eich M, Roos WP, Dianov GL, Digweed M, Kaina B. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide. Mol Pharmacol 2010;78:943-51.
33. Naumann SC, Roos WP,Jost E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009;100:322-33.
34. Bradford MM. A rapid and sensitive method for the quantitation ofmicrogram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
35. Renart J, Reiser J, Stark GR. Transfer of proteins from gels to diazobenzyloxymethyl- paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc Natl Acad Sci U S A 1979;76:3116-20.
36. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010;108:73-112.
37. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010;46:270-83.
38. Batchelor T. Temozolomide for malignant brain tumours. Lancet 2000; 355:1115-6.
39. Ochs K, Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000;60:5815-24.
40. Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski KH, Christmann M, et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS ONE 2013;8:e55665.
41. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide- induced DNA lesion O6-methylguanine. Oncogene 2007; 26:186-97.
42. Barckhausen C, Roos WP, Naumann SC, Kaina B. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair. Oncogene. Epub 2013 Apr 22.
43. Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, et al. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 2004;10:1645-56.
44. Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2013;332:237-48.
45. Lopez-Contreras AJ, Fernandez-Capetillo O. The ATR barrier to replication- born DNA damage. DNA Repair (Amst) 2010;9:1249-55.
46. Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle 2007;6:931-42.
47. Tsuchida R, Yamada T, Takagi M, Shimada A, Ishioka C, Katsuki Y, et al. Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast. Radiat Res 2002; 158:195-201.
48. Tribius S, Pidel A, Casper D. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys 2001;50:511-23.
49. Kheirollahi M, Mehr-Azin M, Kamalian N, Mehdipour P. Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors. Med Oncol 2011;28:7-14.
50. Ivanov VN, Zhou H, Partridge MA, Hei TK. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res 2009;69:3510-9.
51. Wang H, Wang S, Shen L, Chen Y, Zhang X, Zhou J, et al. Chk2 downregulation by promoter hypermethylation in human bulk gliomas. Life ci 2010;86:185-91.
52. Sallinen SL, Ikonen T, Haapasalo H, Schleutker J. CHEK2 mutations in primary glioblastomas. J Neurooncol 2005;74:93-5.
53. Ino Y, Wahrer DC, Bell DW, Haber DA, Louis DN. Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics 2000;3:45-6.
54. Papp T, Niemetz A, Dosdahl N, Kumar K, Schiffmann D. Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol Rep 2007;17:135-40.
55. Seol HJ, Yoo HY, Jin J, Joo KM, Kong DS, Yoon SJ, et al. Prognostic implications of the DNA damage response pathway in glioblastoma.Oncol Rep 2011;26:423-30.
56. Simon M, Ludwig M, Fimmers R, Mahlberg R, Muller-Erkwoh A, Koster G, et al. Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme. Neurosurgery 2006;59:1078-85.
57. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 2010;18:619-29.
58. Bao S,WuQ, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
59. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G (2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001;61:5843-9.
60. Hirose Y, Katayama M, Berger MS, Pieper RO. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J Neurosurg 2004;100:1060-5.
61. Kaina B, Christmann M, Naumann S, Roos WP.MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007;6:1079-99.